Abstract
AbstractExemestane, a 3rd‐generation aromatase inhibitor, has been approved by FDA for the treatment of advanced breast cancer in postmenopausal women since 1995 and its patent was expired in 2015. Since the approval, Exemestane has been widely used in breast cancer patients and is shown to have good clinical effects. There are several published synthesis methods of Exemestane but there is not any such report in Viet Nam. Herein, we describe the two‐step method for the synthesis of Exemestane from the commercial available compound, androst‐4‐ene‐3,17‐dione. The total yield of the synthesized Exemestane is 27.12 %. The structure of Exemestane and intermediate products were elucidated by MS and NMR spectroscopies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
